memantine has been researched along with Retinal Diseases in 4 studies
Retinal Diseases: Diseases involving the RETINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether intraocular pressure (IOP) elevation alters OPA1 expression and triggers OPA1 release, as well as whether the uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist memantine blocks OPA1 release and subsequent apoptotic cell death in glaucomatous DBA/2J mouse retina." | 7.75 | Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. ( Angert, M; Duong-Polk, KX; Ellisman, MH; Ju, WK; Kim, KY; Lindsey, JD; Weinreb, RN, 2009) |
| "To determine whether intraocular pressure (IOP) elevation alters OPA1 expression and triggers OPA1 release, as well as whether the uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist memantine blocks OPA1 release and subsequent apoptotic cell death in glaucomatous DBA/2J mouse retina." | 3.75 | Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. ( Angert, M; Duong-Polk, KX; Ellisman, MH; Ju, WK; Kim, KY; Lindsey, JD; Weinreb, RN, 2009) |
| "Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that was initially indicated for the treatment of moderate to severe Alzheimer's disease." | 2.72 | Memantine and its benefits for cancer, cardiovascular and neurological disorders. ( Abbaszadeh, S; Janssen, PML; Shafiei-Irannejad, V; Soraya, H, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shafiei-Irannejad, V | 1 |
| Abbaszadeh, S | 1 |
| Janssen, PML | 1 |
| Soraya, H | 1 |
| Ito, Y | 1 |
| Nakamura, S | 1 |
| Tanaka, H | 1 |
| Shimazawa, M | 1 |
| Araie, M | 1 |
| Hara, H | 1 |
| Ju, WK | 1 |
| Kim, KY | 1 |
| Angert, M | 1 |
| Duong-Polk, KX | 1 |
| Lindsey, JD | 1 |
| Ellisman, MH | 1 |
| Weinreb, RN | 1 |
| Lagrèze, WA | 1 |
1 review available for memantine and Retinal Diseases
| Article | Year |
|---|---|
Memantine and its benefits for cancer, cardiovascular and neurological disorders.
Topics: Animals; Cardiovascular Diseases; Excitatory Amino Acid Antagonists; Humans; Inflammation; Memantine | 2021 |
3 other studies available for memantine and Retinal Diseases
| Article | Year |
|---|---|
Memantine protects against secondary neuronal degeneration in lateral geniculate nucleus and superior colliculus after retinal damage in mice.
Topics: Animals; Cell Death; Disease Models, Animal; Drug Administration Schedule; Excitatory Amino Acid Ant | 2008 |
Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Survival; Cytochromes c; Dyn | 2009 |
[Neuroprotection. Bases and possibilities of a future clinical use].
Topics: Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Clinical Trials as Topic; Disea | 2001 |